Publication Name	World Journal of Gastroenterology
Manuscript ID	8124
Country	United Kingdom

Received	2013-12-17 15:45
Peer-Review Started	2013-12-18 11:09
To Make the First Decision	2014-01-09 19:21
Return for Revision	2014-01-20 19:06
Revised
Second Decision	2014-04-16 11:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-16 12:09
Articles in Press	2014-05-23 09:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-28 10:14
Publish the Manuscript Online	2014-08-18 16:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies
Manuscript Source	Invited Manuscript
All Author List	Pavlina Spiliopoulou and Hendrik-Tobias Arkenau
Funding Agency and Grant Number
Corresponding Author	Hendrik-Tobias Arkenau, MD, PhD, Director, Drug Development Unit, Sarah Cannon Research Institute United Kingdom, 93 Harley Street, London W1G 6AD, United Kingdom. tobias.arkenau@sarahcannonresearch.co.uk
Key Words	Drug development; Molecularly targeted therapies; Colorectal cancer
Core Tip	Abrogation of the mitogen-activated protein kinase pathway downstream epidermal growth factor receptor (EGFR) has emerged as a new potential targetable pathway in the treatment of metastatic colorectal cancer. Similarly, a variety of agents blocking the PI3K/Akt/mTOR pathway are underway. At the same time, a combinatorial inhibition of angiogenesis is being attempted with dual blockade of vascular-endothelial growth factor and c-mesenchymal-epithelial transition factor. Indications that HER-2 overactivation can confer resistance to treatment to MoAb against EGFR has revealed yet another potential target whereas PARP inhibitors are being tested for their ability to cause synthetic lethality in cancer cells with established defects in MMR system.
Publish Date	2014-08-18 16:49
Citation	Spiliopoulou P, Arkenau HT. Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World J Gastroenterol 2014; 20(30): 10288-10295
URL	http://www.wjgnet.com/1007-9327/full/v20/i30/10288.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i30.10288

Full Article (PDF)	WJG-20-10288.pdf
Full Article (Word)	WJG-20-10288.doc
Manuscript File	8124-Review.docx
Answering Reviewers	8124-Answering reviewers.pdf
Copyright License Agreement	8124-Copyright assignment.pdf
Peer-review Report	8124-Peer reviewer(s).pdf
Scientific Editor Work List	8124-Scientific editor work list.doc